Login to Your Account



Macular Miracle? Ophthotech Raising $167M in Upsized IPO

By Randy Osborne
Staff Writer

Thursday, September 26, 2013
More than doubling the hoped-for take from its initial public offering (IPO), Ophthotech Inc. raised $167 million by selling 7.6 million shares at $22 each for ongoing Phase III work with Fovista (formerly E10030), an antiplatelet-derived growth factor agent that would be used with anti-VEGF therapy in wet age-related macular degeneration (AMD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription